Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 16/20 | 0.85 |
| ▸ | ABL1 | P00519 | 5/20 | 0.85 |
| ▸ | SRC | P12931 | 5/20 | 0.85 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.85 |
| ▸ | EGFR | P00533 | 3/20 | 0.85 |
| ▸ | FYN | P06241 | 3/20 | 0.85 |
| ▸ | YES1 | P07947 | 3/20 | 0.85 |
| ▸ | LYN | P07948 | 3/20 | 0.85 |
| ▸ | HCK | P08631 | 3/20 | 0.85 |
| ▸ | KIT | P10721 | 3/20 | 0.85 |
| ▸ | BCR | P11274 | 3/20 | 0.85 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.85 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.85 |
| ▸ | FGR | P09769 | 2/20 | 0.85 |
| ▸ | JAK3 | P52333 | 2/20 | 0.85 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.85 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.85 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.67 |
| ▸ | CSF1R | P07333 | 2/20 | 0.67 |
| ▸ | RET | P07949 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355730 | 1.00 | LCK (0.85) | LCKABL1SRCMAPK14EGFR | |
| SCHEMBL1704860 | 0.95 | LCK (0.76) | LCKABL1SRCMAPK14EGFR | |
| SCHEMBL20633284 | 0.95 | LCK (0.76) | LCKABL1SRCMAPK14EGFR | |
| SCHEMBL4233014 | 0.94 | LCK (0.76) | LCKABL1SRCMAPK14EGFR | |
| SCHEMBL31060141 | 0.92 | LCK (1.00) | LCKABL1SRCMAPK14EGFR | |
| SCHEMBL774220 | 0.92 | LCK (1.00) | LCKABL1SRCMAPK14EGFR | |
| SCHEMBL22336669 | 0.91 | LCK (0.84) | LCKABL1SRCMAPK14EGFR | |
| SCHEMBL8210337 | 0.91 | LCK (0.84) | LCKABL1SRCMAPK14EGFR | |
| SCHEMBL8217094 | 0.90 | LCK (0.82) | LCKABL1SRCMAPK14EGFR | |
| SCHEMBL14142183 | 0.90 | LCK (0.82) | LCKABL1SRCMAPK14EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800771-B2 | Process for the preparation of dasatinib polymorph | NATCO PHARMA LIMITED (IN) | 2020-10-13 | — | — | US | claimed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| CN-111053916-A | Anti-tumor drug dasatinib-RGD conjugate, preparation method and application thereof | 内蒙古医科大学 | 2020-04-24 | — | — | CN | claimed |
| US-20190292177-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF DASATINIB POLYMORPH | NATCO PHARMA LIMITED (IN) | 2019-09-26 | — | — | US | claimed |
| WO-2018100585-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF DASATINIB POLYMORPH | NATCO PHARMA LIMITED (IN) | 2018-06-07 | — | — | WO | claimed |
| WO-2013065063-A1 | ANHYDROUS FORM OF DASATINIB, PROCESS FOR ITS PREPARATION AND ITS USE | CADILA HEALTHCARE LIMITED (IN) | 2013-05-10 | — | — | WO | claimed |
| EP-3901151-B1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2026-04-01 | — | — | EP | disclosed |
| EP-3643713-B1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-07-30 | — | — | EP | disclosed |
| US-20250163075-A1 | HETEROBIFUNCTIONAL TARGETED PROTEIN DEGRADERS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-05-22 | — | — | US | disclosed |
| US-20250101015-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-03-27 | — | — | US | disclosed |
| US-20250084076-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-03-13 | — | — | US | disclosed |
| US-20250064837-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | SHANGHAITECH UNIVERSITY (CN) | 2025-02-27 | — | — | US | disclosed |
| US-12226424-B2 | Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates | SHANGHAITECH UNIVERSITY (CN) | 2025-02-18 | — | — | US | disclosed |
| US-7189854-B2 | Cyclic protein tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1711481-A2 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20060211705-A1 | 'N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| WO-2006099474-A1 | 'N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO]-5-THIAZOLECARBOXAMIDES METABOLITES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20060004067-A1 | N-(2-chloro-6-methylphenyl)-2-(6-(4-(3-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; high efficiency, high yield process to get 2-aminothiazole-5-carboxamides using halogention reaction; by-products inhibition; anticancer, psoriasis | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050215795-A1 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-29 | — | — | US | disclosed |
| WO-2005077945-A2 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800771-B2 | Process for the preparation of dasatinib polymorph | ABL1, NOP56, SRSF6 | LCK 314/4885ABL1 1/4885SRC 74/4885 |
| US-20060004067-A1 | N-(2-chloro-6-methylphenyl)-2-(6-(4-(3-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; high efficiency, high yield process to get 2-aminothiazole-5-carboxamides using halogention reaction; by-products inhibition; anticancer, psoriasis | TYK2, BRAF, ERBB2 | LCK 29/4885ABL1 6/4885SRC 55/4885 |
| US-20050215795-A1 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | MAP3K5, MAP3K2, MAP3K20 | LCK 58/4885ABL1 26/4885SRC 54/4885 |
| US-20190292177-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF DASATINIB POLYMORPH | NOP56, ABL1, SRSF6 | LCK 315/4885ABL1 2/4885SRC 106/4885 |
| US-20250064837-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | UFM1, SUMO1, SUMO2 | LCK 3673/4885ABL1 3044/4885SRC 1668/4885 |
| US-12226424-B2 | Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates | UFM1, SUMO1, SUMO2 | LCK 3730/4885ABL1 3132/4885SRC 1824/4885 |
| US-20250163075-A1 | HETEROBIFUNCTIONAL TARGETED PROTEIN DEGRADERS | KLHDC2, KLHL6, KLHL20 | LCK 3954/4885ABL1 4051/4885SRC 2577/4885 |
| US-20060211705-A1 | 'N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites | IL2, TPMT, HNMT | LCK 237/4885ABL1 164/4885SRC 1909/4885 |
| US-20250101015-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | LCK, SRC, CILK1 | LCK 1/4885ABL1 8/4885SRC 2/4885 |
| US-20250084076-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | LCK, SRC, CILK1 | LCK 1/4885ABL1 8/4885SRC 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.